Evaluation of the effect of curcumin-piperine supplement in septic patients
Phase 3
Recruiting
- Conditions
- sepsis.Other sepsis
- Registration Number
- IRCT20201220049774N3
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Age between 18 and 80 years
Having sepsis and being admitted to the intensive care unit
Signing an informed consent form
Exclusion Criteria
Pregnancy and lactation
History of allergy to turmeric and curcumin products
Age under 18 years
HIV patients
Member transplant history
Rheumatic or autoimmune disease
Patients treated with immunosuppressive drugs
Patients treated with corticosteroids
Radiotherapy
Solid or malignant tumor
Concomitant use of any supplement with antioxidant or anti-inflammatory effect or immune system regulator
Patients without oral / nasal gastrointestinal tract
White blood cell count less than 1000 / microliter
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Lactate. Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;C-reactive protein (CRP). Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;SOFA score(Sequential organ failure assessment). Timepoint: At the beginning of the study and after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.
- Secondary Outcome Measures
Name Time Method